Neurobiological Chooses SCIREX to Manage Phase III Trials of Viprinex

Neurobiological Technologies (NTI) has selected SCIREX as its contract research organization to manage its Phase III clinical program for Viprinex (Ancrod).

Viprinex, a purified extract of a specific snake venom, was previously studied in approximately 2,000 patients in various clinical studies in the U.S. and Europe.

NTI is instituting a new program with a six-hour treatment window based on a different dose and dosing regimen. Currently, the only available therapy for ischemic stroke must be administered within three hours, significantly limiting the number of patients that may be treated.

Details of the trial will be made public pending a final protocol agreement with the FDA. It is anticipated that Phase III trials will begin this summer.